Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 11-20 results of 48
Head and Neck Cancer

ECOG-ACRIN / EA3191

Official Title: Testing What Happens When An Immunotherapy Drug (Pembrolizumab) Is Added To Radiation Or Given By Itself Compared To The Usual Treatment Of Chemotherapy With Radiation After You Have Had Surgery For Your Recurrent Squamous Cell Carcinoma Of The Head And Neck
Study Purpose: To compare usual approach (chemotherapy plus radiation) to pembrolizumab alone and pembrolizumab in combination with radiation after having head and neck cancer surgically removed.
Status: Recruiting
Head and Neck Cancer Other Trials

ECOG-ACRIN / EA3231

Official Title: A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
Study Purpose: To determine if cabozantinib or the combination of dabrafenib and trametinib works better to prolong the time until the tumor grows or spreads after initial treatment stops working.
Status: Recruiting
Lung Cancer

ECOG-ACRIN / EA5162

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions.
Status: Recruiting
Skin Cancer

ECOG-ACRIN / EA6141

Official Title: Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma
Study Purpose: To compare any good and bad effects of giving three drugs- ipilimumab, nivolumab, and sargramostim at the same time compared to just ipilimumab and nivolumab together.
Status: Recruiting
Breast Cancer

Gilead / GS-US-595-6184

Official Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)
Status: Recruiting
Gynecologic Cancer

GOG Foundation GOG-3127 / AstraZeneca D8891C0001 (TREVI)

Official Title: A Randomized, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
Study Purpose: To find out about the safety and efficacy (how well a drug works) of AZD5335 for the treatment of platinum-resistant ovarian cancer by comparing AZD5335 to standard of care therapies.
Status: Recruiting
Gynecologic Cancer

GOG FOUNDATION- GOG-3103/Trofuse-022 MK-2870-022

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer
Study Purpose: To test the safety, efficacy, and effect on quality of life of sac-TMT when given alone, with bevacizumab, or compared to no maintenance treatment.
Status: Recruiting
Gynecologic Cancer

GOG-3102/MK2870-021

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance with or without Bevacizumab versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy
Study Purpose: To test the safety of sac-TMT when given alone or with bevacizumab; to see how well sac-TMT +/- bevacizumab works compared to standard of care treatment; and to compare the quality of life of participants receiving the study treatment vs. standard of care treatment
Gynecologic Cancer

Gradalis / CL-PTL-135

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research
Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.
Status: Recruiting
Head and Neck Cancer

GSK 221530

Official Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Study Purpose: To evaluate the efficacy of dostarlimab as sequential therapy following CRT as compared to placebo in participants with PD-L1 positive LA unresected HNSCC 
Status: Recruiting